Cagrilintide

Cagrilintide is a research-grade analog of the endogenous hormone amylin, investigated for its role in appetite regulation, body weight reduction, and metabolic health. It is commonly studied in combination with GLP-1–based therapies for synergistic weight management effects.

Mechanism and Metabolic Effects

• Acts as a long-acting amylin receptor agonist, enhancing satiety signaling, slowing gastric emptying, and reducing food intake in experimental obesity models.

• Research associates cagrilintide with improvements in body weight, waist circumference, and metabolic markers when used alone or alongside incretin-based agents in clinical-style studies.

Weight and Appetite Research

• Produces dose-dependent body weight loss primarily through reduced caloric intake rather than stimulant-like thermogenesis, making it valuable for studying sustained appetite suppression.

• Experimental data suggest potential benefits for hedonic eating control and reduced cravings, supporting its use in research on long-term adherence to hypocaloric regimens.

For research purposes only. Not intended for human consumption.